Shopping Cart
- Remove All
Your shopping cart is currently empty
CKI-7 free base
😃Good
Catalog No. T10829Cas No. 120615-25-0
Alias CKI-7
CKI-7 free base is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor, also inhibiting SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.
CKI-7 free base
😃Good
Catalog No. T10829Alias CKI-7Cas No. 120615-25-0
CKI-7 free base is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor, also inhibiting SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $88 | 5 days | |
| 1 mL x 10 mM (in DMSO) | $128 | 5 days |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CKI-7 free base"
Emodin
Cited
Frangula emodin
T2869518-82-1
Emodin (Frangula emodin) is a naturally occurring anthraquinone present in the roots and barks of numerous plants; exerts antiproliferative effects in Y cells that are regulated by different signaling pathways.
- $45
Size
QTY
CitedLY294002
Cited
SF 1101, NSC 697286, LY 294002
T2008154447-36-6
LY294002 (SF 1101) is a broad-spectrum inhibitor of PI3K, inhibiting PI3Kα, PI3Kδ, and PI3Kβ (IC50=0.5/0.57/0.97 μM). LY294002 is also an inhibitor of DNA-PK (IC50=1.4 μM) and an inhibitor of CK2 (IC50=98 nM). LY294002 activates apoptosis and autophagy.
- $34
Size
QTY
CitedTBCA
Casein Kinase II Inhibitor III, TBCA
T21915934358-00-6In house
TBCA (Casein Kinase II Inhibitor III, TBCA) is a highly selective CK2 (casein kinase II) inhibitor, IC50 = 110 nM, Ki = 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases.
- $45
Size
QTY
LY-364947
Cited
LY 364947, HTS466284
T2048396129-53-6
LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I.
- $59
Size
QTY
CitedAS-252424 Cited
T6208900515-16-4
AS-252424 is a potent and selective inhibitor of PI3Kγ with an IC50 of 33 nM and demonstrates over 10-fold selectivity for PI3Kγ versus PI3Kα.
- $33
Size
QTY
CitedCasein Kinase II Inhibitor IV
T10687863598-09-8In house
Casein Kinase II Inhibitor IV is an inducer of epidermal keratinocyte differentiation.
- $79
Size
QTY
Ellagic acid Cited
Gallogen, Elagostasine
T0465476-66-4
Ellagic acid (Gallogen), a thickened tetracyclic natural product, is a potent CK2 inhibitor (IC50=40 nM; Ki=20 nM) with ATP-competitive properties. Ellagic acid is an antioxidant and also possesses antiproliferative activity.
Carbonic AnhydraseCasein KinaseEndogenous MetaboliteHedgehog/SmoothenedPKAPKCReactive Oxygen SpeciesSykTopoisomerase
- $44
Size
QTY
CitedCK2/ERK8-IN-1
TMCB
T108271085822-09-8In house
CK2/ERK8-IN-1 (TMCB) is a dual inhibitor of casein kinase 2 (CK2) (Ki: 0.25 µM) and ERK8 (IC50s: 0.50 μM) with pro-apoptotic efficacy. CK2/ERK8-IN-1 also binds to PIM1, DYRK1A, and HIPK2 (Kis: 8.65 µM, 11.9 µM, and 15.25 µM).
- $30
Size
QTY
TA-01
T46451784751-18-3
TA-01 is a potent inhibitor of CK1 and p38 MAPK, with IC50 values of 6.4 nM for CK1ε, 6.8 nM for CK1δ, and 6.7 nM for p38 MAPK.
- $30
Size
QTY
CK2-IN-4
T73375313985-59-0
CK2-IN-4 is a protein kinase (CK2) inhibitor with an IC50 value of 8.6 µM. CK2-IN-4 has potential anticancer ah and anti-inflammatory activity for the study of viral infections and glomerulonephritis diseases.
- $31
Size
QTY
CK2α-IN-1
T73269443747-52-2
CK2α-IN-1 is a selective non-ATP-competitive CK2α inhibitor with an IC50 of 7.0 µM and a Ki of 1.6 µM.CK2α-IN-1 exhibits potential anticancer activity and can be used in cancer research.
- $36
Size
QTY
Casein kinase 1δ-IN-6
T775001579991-01-7
Casein kinase 1δ-IN-6 is a potent and selective inhibitor of the protein kinase CK-1δ with an IC50 of 23 nM, demonstrating neuroprotective and anti-inflammatory activity in both in vitro and in vivo assays. Casein kinase 1δ-IN-6 can be used to study neurodegenerative diseases.
- $129
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | CKI-7 free base is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor, also inhibiting SGK, ribosomal S6 kinase-1 (S6K1), and MSK1. |
| Targets&IC50 | CK1:6 μM, CK1:8.5 μM (ki) |
| In vitro | The treatment of CKI-7 (0.1-10 μM; 5 days; ES cells) significantly increases the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers βIII-tubulin and nestin, in a concentration-dependent manner. CKI-7 (5 μM; 5 days; ES cells) treatment suppresses SFEB-induced β-catenin stabilization on day 5 [1]. |
| In vivo | In vivo dose-dependent, the anti-tumor activity of CKI-7 is demonstrated in a SCID-Beige mouse systemic tumor model utilizing isolated Philadelphia chromosome-positive acute lymphoblastic leukemia cell line. Exposure to CKI-7 results in a cell cycle-dependent caspase 3 activation and apoptotic cell death [2]. |
| Alias | CKI-7 |
| Molecular Weight | 285.75 |
| Formula | C11H12ClN3O2S |
| Cas No. | 120615-25-0 |
| Relative Density. | 1.31g/cm3 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (87.49 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CKI-7 free base | purchase CKI-7 free base | CKI-7 free base cost | order CKI-7 free base | CKI-7 free base chemical structure | CKI-7 free base in vivo | CKI-7 free base in vitro | CKI-7 free base formula | CKI-7 free base molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.